Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,848 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S; I-SPY 2 Trial Consortium; Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF. Yau C, et al. Among authors: dunn j. Lancet Oncol. 2022 Jan;23(1):149-160. doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 11. Lancet Oncol. 2022. PMID: 34902335 Free PMC article.
Etoposide protein binding in cancer patients.
Liu B, Earl HM, Poole CJ, Dunn J, Kerr DJ. Liu B, et al. Among authors: dunn j. Cancer Chemother Pharmacol. 1995;36(6):506-12. doi: 10.1007/BF00685801. Cancer Chemother Pharmacol. 1995. PMID: 7554043
Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.
Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, Spooner DA, Agrawal RK, Fernando IN, Brunt AM, O'Reilly SM, Crawford SM, Rea DW, Simmonds P, Mansi JL, Stanley A, Harvey P, McAdam K, Foster L, Leonard RC, Twelves CJ; NEAT Investigators and the SCTBG. Poole CJ, et al. Among authors: dunn ja. N Engl J Med. 2006 Nov 2;355(18):1851-62. doi: 10.1056/NEJMoa052084. N Engl J Med. 2006. PMID: 17079759 Free article. Clinical Trial.
National randomised controlled trial is needed.
Donnelly PK, Hiller L, Dunn JA. Donnelly PK, et al. BMJ. 2008 Mar 1;336(7642):461-2. doi: 10.1136/bmj.39500.469664.1F. BMJ. 2008. PMID: 18309966 Free PMC article. No abstract available.
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).
Bartlett JM, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ, Cameron DA, Thomas J, Campbell FM, Rea DW, Provenzano E, Caldas C, Pharoah P, Hiller L, Earl H, Poole CJ. Bartlett JM, et al. Among authors: dunn ja. Lancet Oncol. 2010 Mar;11(3):266-74. doi: 10.1016/S1470-2045(10)70006-1. Epub 2010 Jan 13. Lancet Oncol. 2010. PMID: 20079691 Free article.
The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses.
Campbell HE, Epstein D, Bloomfield D, Griffin S, Manca A, Yarnold J, Bliss J, Johnson L, Earl H, Poole C, Hiller L, Dunn J, Hopwood P, Barrett-Lee P, Ellis P, Cameron D, Harris AL, Gray AM, Sculpher MJ. Campbell HE, et al. Among authors: dunn j. Eur J Cancer. 2011 Nov;47(17):2517-30. doi: 10.1016/j.ejca.2011.06.019. Epub 2011 Jul 7. Eur J Cancer. 2011. PMID: 21741831
Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial.
Bartlett J, Canney P, Campbell A, Cameron D, Donovan J, Dunn J, Earl H, Francis A, Hall P, Harmer V, Higgins H, Hillier L, Hulme C, Hughes-Davies L, Makris A, Morgan A, McCabe C, Pinder S, Poole C, Rea D, Stallard N, Stein R. Bartlett J, et al. Among authors: dunn j. Clin Oncol (R Coll Radiol). 2013 Feb;25(2):109-16. doi: 10.1016/j.clon.2012.10.005. Epub 2012 Dec 23. Clin Oncol (R Coll Radiol). 2013. PMID: 23267818 Review.
Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial.
Ali AM, Provenzano E, Bartlett JM, Abraham J, Driver K, Munro AF, Twelves C, Poole CJ, Hiller L, Dunn JA, Earl HM, Caldas C, Pharoah PD. Ali AM, et al. Among authors: dunn ja. Int J Cancer. 2013 Sep 15;133(6):1470-8. doi: 10.1002/ijc.28150. Epub 2013 Apr 18. Int J Cancer. 2013. PMID: 23483540 Free article.
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.
Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, Swinson D, Falk S, Chau I, Cunningham D, Kareclas P, Cook N, Blazeby JM, Dunn JA; COUGAR-02 Investigators. Ford HE, et al. Among authors: dunn ja. Lancet Oncol. 2014 Jan;15(1):78-86. doi: 10.1016/S1470-2045(13)70549-7. Epub 2013 Dec 10. Lancet Oncol. 2014. PMID: 24332238 Free article. Clinical Trial.
3,848 results